Adverse events
Total number of AEs was significantly greater in the varenicline group than in the placebo group (246 vs. 154; No significant changes in mean (SD) systolic and diastolic blood pressure, and resting heart rate were observed between and within treatment groups ( Additional file Measures of the urge to vape across the treatment phase of this study were consistently attenuated with varenicline; at week-4, MNWS craving sub-score of 0.56 (0–2) in the varenicline group was significantly lower than 1.61 (0–2.75) (